Engineered immune cells take on lupus in first human trial
NCT ID NCT06892145
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goals are to check safety and find the right dose, while also looking for signs that lupus symptoms improve.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
RECRUITINGHefei, Anhui, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Can a drug duo outsmart resistant lymphomas?
- Custom-Made vaccine aims to boost immune attack on kidney tumors